Competent Cells Market Size To Reach $3.59 Billion By 2030

Competent Cells Market Growth & Trends

The global competent cells market size is anticipated to reach USD 3.59 billion by 2030, exhibiting a CAGR of 8.10% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing biopharmaceutical research, advancements in gene editing technologies, and the expanding field of synthetic biology is expected to propel market growth. Moreover, the biotechnology and pharmaceutical industries depend heavily on competent cells for the production of recombinant proteins, enzymes, and vaccines. The growing need for these products in medical treatments, research, and industrial applications fuels the demand for competent cells.

The COVID-19 pandemic has significantly boosted the market for competent cells, as companies increased their research and development efforts to address immediate health and scientific challenges. Competent cells, vital for tasks like molecular cloning, genetic engineering, and making recombinant proteins, have been in higher demand due to their key role in creating vaccines, diagnostic tests, and therapeutic research. The urgent need for vaccine manufacturing and treatments for COVID-19 has driven biotech and pharmaceutical companies to improve their cloning processes. These factors have impelled the growth of the market and are anticipated to propel exponentially over the forecast period.

In addition, technological advancements in cell preparation are projected to further propel the demand for competent cells. Technological advancements in the preparation and transformation efficiency of competent cells have significantly impacted the performance and reliability of competent cells, thus increasing the demand for researchers and industrial users. Additionally, genetic modifications and stress response pathway developments have further boosted transformation accomplishment, providing tailored solutions for specific applications, and advancing the utility of competent cells in various fields. These factors are thus projected to impel the growth of the market over the forecast period.

However, the high cost of producing and maintaining high-efficiency competent cells is considerable, which may limit their accessibility, especially for smaller research institutions and startups with limited budgets. This is anticipated to affect the adoption rate of competent cells in certain markets. Moreover, the process of preparing competent cells and accomplishing successful transformations could be technically complex and involve specialized knowledge and equipment. Thereby, hampering the growth of the market over the forecast period.

 Request a free sample copy or view report summary: Competent Cells Market Report

Competent Cells Market Report Highlights

• The chemically competent cells segment held the largest market share of 43.62% in 2023 due to their wide use in the field of recombinant DNA technology, and molecular biology. On the other hand, electrocompetent cells are anticipated to grow at the fastest CAGR over the forecast period.

• In 2023, the cloning segment is anticipated to dominate the market share for the application segment. However, the protein expression segment is expected to grow at the fastest CAGR of 9.04% over the forecast period driven by the increasing demand for recombinant proteins and enzymes required in various industrial and academic applications.

• The pharmaceutical & biotechnology companies segment dominated the end-use segment with the largest share in 2023 due to the rising demand for competent cells for drug discovery and development, along with the few qualitative tests required to fulfill the regulatory standards.

• The North America region dominated the market with a share of 34.13% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Competent Cells Market Segmentation

Grand View Research has segmented the global competent cells market based on type, application, end-use, and region:

Competent Cells Type Outlook (Revenue, USD Million, 2018 - 2030)

• Chemically Competent Cells

• Electrocompetent Cells

• Ultracompetent Cells

Competent Cells Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cloning

• Protein Expression

• Mutagenesis

• Others

Competent Cells End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Others

Competent Cells Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Competent Cells Market

• Thermo Fisher Scientific

• Merck KGaA

• Agilent Technologies, Inc.

• Takara Bio Inc.

• New England Biolabs (UK) Ltd.

• Promega Corporation

• Bio-Rad Laboratories

• Roche Applied Science

• Qiagen

• SGI-DNA (Synthetic Genomics, Inc.)